Letter by Wang Regarding Article, “Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond?”
Could pathophysiology failure be ruled out?
Editorial : Function of renal sympathetic nerves
It may be not suitable to perform renal denervation in renal arteries with significant stenosis
The association between serum uric acid and blood pressure in different age groups in a healthy Chinese cohort
The penetration of methanol into bovine cardiac and hepatic tissues is faster than ethanol and formalin
The concentration of ethanol affects its penetration rate in bovine cardiac and hepatic tissues
Comment : Translating guidelines into practice : Interpreting the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL cholesterol lowering in the management of atherosclerotic cardiovascular disease risk
Renal denervation promotes atherosclerosis in hypertensive apolipoprotein E-Deficient mice infused with angiotensin II
Limitations in current clinical trials on renal denervation
It is urgent to investigate predictors of the response of blood pressure to renal denervation
Ambulatory blood pressure may be designed as the primary efficacy outcome in clinical trials on renal denervation
Single-sided renal denervation may be not suitable for patients with significant renal artery stenosis
What is the true incidence of renal artery stenosis after sympathetic denervation?
Is isolated systolic hypertension an indication for renal denervation?
Are you sure you would like to clear your session, including search history and login status?